Disc Medicine
Presence
Disc Medicine is one of the...
Disc Medicine is a company listed under the stock ticker IRON (US).
Acquisition, funding and merger involving Disc Medicine.
- Disc Medicine has just announced a $60 Million fundraising (posted on February 17 2023).
Executives
View the org chart displaying its 20 main executives
Most searched biographies at Disc Medicine
- John Quisel, Chief Executive Officer and Director
- Donald Nicholson, Executive Chairman of the Board
- Kevin Bitterman, Director
Popular executive movements at Disc Medicine
- Pamela Stephenson has joined the company as Chief Commercial Officer (posted on February 27 2024).
- Joanne Bryce, who is Chief Financial Officer will soon leave the company (posted on October 24 2023).
Create your alert
to follow the executive moves at Disc Medicine.
Biotechnology
Disc Medicine has 2,284 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Karius has just announced a $100 Million fundraising (posted on May 3 2024).
- Transcarent has just announced a $126 Million fundraising (posted on May 2 2024).
- WindRose Health Investors has announced the acquisition of SubjectWell (posted on May 2 2024).
Popular contacts in Biotechnology
News
Press releases by Disc Medicine
- Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) | Disc Medicine Inc.
- Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | Disc Medicine Inc.
- Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024 | Disc Medicine Inc.
- Disc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP) - Disc Medicine
- Disc Medicine Announces Several Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting - Disc Medicine
- Disc Medicine Announces Multiple Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting - Disc Medicine
- Disc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP) - Disc Medicine
- Disc Medicine Initiates BEACON, a Phase 2 Clinical Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP) - Disc Medicine
- Gemini Therapeutics and Disc Medicine Announce Merger Agreement - Disc Medicine
- Disc Medicine Initiates Phase 1b/2 Clinical Study of DISC-0974 in Myelofibrosis Patients with Severe Anemia - Disc Medicine
- View more press releases Close
Social media about Disc Medicine
- Disc Medicine on Wikipedia, Google News & Yahoo Finance
- Disc Medicine on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including John Quisel 
Call Disc Medicine at +1 617...
